Filing summary
Entity and period: The source filing is Movano Inc.’s unaudited Form 10-Q for the three months ended March 31, 2023, filed May 15, 2023. It does not identify Corvex, Inc.; confirm the intended company before relying on this summary. Movano is a development-stage health-technology company and reported no revenue.
Financial performance and position
- Revenue and margins: No revenue was recorded; operating and gross margins are therefore not meaningful. Operating expenses were $7.203 million.
- Loss: Net loss was $7.096 million, or $0.19 per basic and diluted share, versus $6.932 million, or $0.21 per share, in Q1 2022.
- Operating expenses: Research and development was $3.894 million, down from $4.591 million. Sales, general and administrative expense was $3.309 million, up from $2.347 million.
- Cash flow: Operating activities used $6.080 million, compared with $5.782 million used in Q1 2022. Investing activities used $13,000; financing activities provided $9.603 million. Cash increased by $3.510 million during the quarter.
- Liquidity and debt: Cash and cash equivalents were $14.269 million at quarter-end, versus $10.759 million at December 31, 2022. Current liabilities were $5.340 million and total liabilities were $5.610 million. The balance sheet reports no borrowing or debt balance; lease liabilities were $377,000 in total.
- Equity financing: The company received approximately $6.7 million net from a February public offering and $2.8 million net through its at-the-market program. It issued 7.7 million shares during the quarter through these offerings; 41.4 million shares were outstanding at March 31.
Changes versus the prior-year quarter
- Total operating expenses rose $265,000 and net loss increased $164,000. Lower R&D spending was more than offset by higher general and administrative expenses.
- Cash used in operations increased by $298,000. Financing cash flow shifted from zero in Q1 2022 to $9.603 million in Q1 2023, primarily from equity issuance.
- Basic and diluted loss per share improved to $0.19 from $0.21, partly reflecting a higher weighted-average share count.
Outlook, risks, and notable items
- Going concern: Management states that cash is not expected to be sufficient to complete development and commercialization of the Evie Ring. The filing says substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements. Additional financing will be needed; availability and terms are uncertain.
- Product plans: Movano was developing the Evie Ring and said it was on track to submit its first FDA application for heart and blood-oxygen metrics in June 2023. It was also conducting trials and developing algorithms for its sensor technology aimed at non-invasive glucose and cuffless blood-pressure monitoring. These are plans, not achieved clearances or commercial results.
- Funding capacity and dilution: Approximately $44.8 million remained available under the $50 million ATM program at March 31. Further equity issuance could dilute shareholders; debt financing or partnerships could carry restrictions or require concessions.
- Controls: Disclosure controls were deemed ineffective at March 31 due to a previously identified material weakness in financial close and reporting controls, including account reviews and information-technology general controls. Remediation efforts were ongoing.
- Other exposures: The company relies on third-party manufacturers and disclosed deposits exceeding insured limits. It cited potential risks from banking-sector disruption, macroeconomic conditions, competition, regulatory approvals, and product development and commercialization. It reported no litigation believed to have a material adverse effect and $0.4 million of non-cancelable commitments.
Important facts for investors to verify
- Confirm that Movano Inc. is the intended issuer, given the request names Corvex, Inc.
- Review subsequent filings for actual cash burn, financing activity, and updated going-concern disclosures.
- Verify whether the planned June 2023 FDA submission occurred and whether any clearance or launch milestones followed.
- Assess the material weakness remediation and monitor share-count changes, ATM sales, and outstanding warrants and options.